Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine ( 131 I-MIBG) therapy for neuroblastoma.
dc.contributor.author | Quach, Alekist | en_US |
dc.contributor.author | Ji, Lingyun | en_US |
dc.contributor.author | Mishra, Vikash | en_US |
dc.contributor.author | Sznewajs, Aimee | en_US |
dc.contributor.author | Veatch, Janet | en_US |
dc.contributor.author | Huberty, John | en_US |
dc.contributor.author | Franc, Benjamin L. | en_US |
dc.contributor.author | Sposto, Richard | en_US |
dc.contributor.author | Groshen, Susan | en_US |
dc.contributor.author | Wei, Denice | en_US |
dc.contributor.author | Fitzgerald, Paul | en_US |
dc.contributor.author | Maris, John M. | en_US |
dc.contributor.author | Yanik, Gregory A. | en_US |
dc.contributor.author | Hawkins, Randall A. | en_US |
dc.contributor.author | Villablanca, Judith G. | en_US |
dc.contributor.author | Matthay, Katherine K. | en_US |
dc.date.accessioned | 2011-01-04T16:24:26Z | |
dc.date.available | 2012-02-21T18:47:01Z | en_US |
dc.date.issued | 2011-02 | en_US |
dc.identifier.citation | Quach, Alekist; Ji, Lingyun; Mishra, Vikash; Sznewajs, Aimee; Veatch, Janet; Huberty, John; Franc, Benjamin; Sposto, Richard; Groshen, Susan; Wei, Denice; Fitzgerald, Paul; Maris, John M.; Yanik, Gregory; Hawkins, Randall A.; Villablanca, Judith G.; Matthay, Katherine K. (2011). "Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine ( 131 I-MIBG) therapy for neuroblastoma." Pediatric Blood & Cancer 56(2): 191-201. <http://hdl.handle.net/2027.42/78497> | en_US |
dc.identifier.issn | 1545-5009 | en_US |
dc.identifier.issn | 1545-5017 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/78497 | |
dc.description.abstract | Background 131 I-Metaiodobenzylguanidine ( 131 I-MIBG) provides targeted radiotherapy for children with neuroblastoma, a malignancy of the sympathetic nervous system. Dissociated radioactive iodide may concentrate in the thyroid, and 131 I-MIBG is concentrated in the liver after 131 I-MIBG therapy. The aim of our study was to analyze the effects of 131 I-MIBG therapy on thyroid and liver function. Procedure Pre- and post-therapy thyroid and liver functions were reviewed in a total of 194 neuroblastoma patients treated with 131 I-MIBG therapy. The cumulative incidence over time was estimated for both thyroid and liver toxicities. The relationship to cumulative dose/kg, number of treatments, time from treatment to follow-up, sex, and patient age was examined. Results In patients who presented with Grade 0 or 1 thyroid toxicity at baseline, 12 ± 4% experienced onset of or worsening to Grade 2 hypothyroidism and one patient developed Grade 2 hyperthyroidism by 2 years after 131 I-MIBG therapy. At 2 years post- 131 I-MIBG therapy, 76 ± 4% patients experienced onset or worsening of hepatic toxicity to any grade, and 23 ± 5% experienced onset of or worsening to Grade 3 or 4 liver toxicity. Liver toxicity was usually transient asymptomatic transaminase elevation, frequently confounded by disease progression and other therapies. Conclusion The prophylactic regimen of potassium iodide and potassium perchlorate with 131 I-MIBG therapy resulted in a low rate of significant hypothyroidism. Liver abnormalities following 131 I-MIBG therapy were primarily reversible and did not result in late toxicity. 131 I-MIBG therapy is a promising treatment for children with relapsed neuroblastoma with a relatively low rate of symptomatic thyroid or hepatic dysfunction. Pediatr Blood Cancer 2011;56:191–201. © 2010 Wiley-Liss, Inc. | en_US |
dc.format.extent | 175815 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine ( 131 I-MIBG) therapy for neuroblastoma. | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pediatrics, University of Michigan and Mott Children's Hospital, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Pediatrics, UCSF Children's Hospital, University of California, San Francisco, California | en_US |
dc.contributor.affiliationother | Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California | en_US |
dc.contributor.affiliationother | Department of Pediatrics, UCSF Children's Hospital, University of California, San Francisco, California | en_US |
dc.contributor.affiliationother | Department of Pediatrics, UCSF Children's Hospital, University of California, San Francisco, California | en_US |
dc.contributor.affiliationother | Department of Pediatrics, UCSF Children's Hospital, University of California, San Francisco, California | en_US |
dc.contributor.affiliationother | Nuclear Medicine Program, Department of Radiology, University of California San Francisco, UCSF Children's Hospital, San Francisco, California | en_US |
dc.contributor.affiliationother | Nuclear Medicine Program, Department of Radiology, University of California San Francisco, UCSF Children's Hospital, San Francisco, California | en_US |
dc.contributor.affiliationother | Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California ; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California | en_US |
dc.contributor.affiliationother | Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California | en_US |
dc.contributor.affiliationother | Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California | en_US |
dc.contributor.affiliationother | Department of Pediatrics, UCSF Children's Hospital, University of California, San Francisco, California | en_US |
dc.contributor.affiliationother | Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania ; University of Pennsylvania, Philadelphia, Pennsylvania | en_US |
dc.contributor.affiliationother | Nuclear Medicine Program, Department of Radiology, University of California San Francisco, UCSF Children's Hospital, San Francisco, California | en_US |
dc.contributor.affiliationother | Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California | en_US |
dc.contributor.affiliationother | Department of Pediatrics, UCSF Children's Hospital, University of California, San Francisco, California ; Department of Pediatrics, University of California San Francisco, 505 Parnassus, M647, San Francisco, CA 94143-0106. | en_US |
dc.identifier.pmid | 20830775 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/78497/1/22767_ftp.pdf | |
dc.identifier.doi | 10.1002/pbc.22767 | en_US |
dc.identifier.source | Pediatric Blood & Cancer | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.